It is quite obvious that bone morbidity has a negative impact on our patients with breast cancer. The use of bone-modifying agents in this setting can yield significant quality-of-life benefits.
Aasems Jacob, MD
Advertisement
Articles by Aasems Jacob, MD
Advertisement
Latest Updated Articles
- Optimal Use of Bone-Targeted Agents in Breast Cancer
August 15th 2016
Advertisement
Advertisement
Trending on CancerNetwork
1
AI and MRD Take Center Stage on Day 2 of ASCO Breakthrough 2026
2
Cellular Therapy and Antibody-Drug Conjugates Shape Day 1 of ASCO Breakthrough 2026
3
42 Intraoperative Frozen Analysis of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy Does Not Provide Additional Surgical Benefit and Increases the Rate of Unnecessary ALND in Clinically Node-Negative Breast Cancer Patients
4
41 Unexpected While Expecting: Rare Case of Pregnancy Associated Xanthogranulomatous Mastitis Masquerading as Malignancy
5